HTG Molecular Diagnostics IncOver The Counter Market:HTGMQ
- LAST PRICE0.0003
- TODAY'S CHANGE (%)-0.0001 (-25.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0003 / 0.0004
- Day Range
- 52 Week Range
- Volume2,158
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HTGMQ |
|---|---|---|
| 10:49 ET | 1000 | 0.0003 |
| 11:16 ET | 416 | 0.0003 |
| 12:01 ET | 300 | 0.0003 |
| 12:15 ET | 206 | 0.0003 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
HTG Molecular Diagnostics Inc | 890.0 | 0.0x | --- |
Viveve Medical Inc | 1.1K | 0.0x | --- |
Medite Cancer Diagnostics Inc | 90.0 | 0.0x | --- |
G Medical Innovations Holdings Ltd | 2.5K | --- | --- |
Leafbuyer Technologies Inc | 1.6M | -1.8x | --- |
Avinger Inc | 2.5M | -0.1x | --- |
Company Information
HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.
Contact Information
- Headquarters
- 3430 E Global LoopTUCSON, AZ, United States 85706-5009
- Phone
- ---
- Fax
- 520-547-2837
Executives
- Independent Chair of Board of Directors
- Ann Hanham
- President, Chief Executive Officer, Director
- John Lubniewski
- Senior Vice President, Chief Financial Officer, Treasurer, Secretary
- Shaun Mcmeans
- Senior Vice President of Therapeutics , Executive Officer
- Stephen Barat
- Independent Director
- Thomas Dubensky
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $890.00 |
|---|---|
Revenue (TTM) | $6.2M |
Shares Outstanding | 2.2M |
HTG Molecular Diagnostics Inc does not pay a dividend. | |
Beta | 2.66 |
EPS | $-18.08 |
Book Value | $2.44 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -315.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
